Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of ifinatamab deruxtecan in advanced solid tumors
jRCT2080224907Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of ifinatamab deruxtecan in head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), non-small cell lung cancer (NSCLC) and 7 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Oct 2019; status: completed.
02
Drugs
ifinatamab deruxtecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)bladder cancer
Beyond the preview
Go deeper on jRCT2080224907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224907.